Inotek Pharmaceuticals (NASDAQ:ITEK) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday.
Separately, Zacks Investment Research downgraded shares of Inotek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th.
Shares of Inotek Pharmaceuticals (NASDAQ:ITEK) traded down $0.16 during trading hours on Friday, hitting $3.04. 394,100 shares of the stock traded hands, compared to its average volume of 753,067. The stock has a market cap of $340.28 and a P/E ratio of -2.19. The company has a quick ratio of 27.63, a current ratio of 27.63 and a debt-to-equity ratio of 0.97. Inotek Pharmaceuticals has a twelve month low of $0.85 and a twelve month high of $3.80.
A number of hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP raised its position in Inotek Pharmaceuticals by 135.0% in the 3rd quarter. GSA Capital Partners LLP now owns 367,300 shares of the biotechnology company’s stock valued at $654,000 after purchasing an additional 211,000 shares during the last quarter. Pura Vida Investments LLC purchased a new stake in Inotek Pharmaceuticals in the 3rd quarter valued at $2,039,000. Point72 Asset Management L.P. purchased a new stake in Inotek Pharmaceuticals in the 3rd quarter valued at $1,131,000. Boothbay Fund Management LLC raised its position in Inotek Pharmaceuticals by 94.0% in the 3rd quarter. Boothbay Fund Management LLC now owns 139,731 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 67,687 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in Inotek Pharmaceuticals in the 3rd quarter valued at $2,771,000. Hedge funds and other institutional investors own 37.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3127571/inotek-pharmaceuticals-itek-upgraded-by-bidaskclub-to-strong-buy.html.
About Inotek Pharmaceuticals
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Ratings for Inotek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.